Table 1

Expression of chemokine receptors by peripheral blood T cells in MS patients

ReceptorsDouble-positive cells, %
ControlsRR MSProgressive MS
CD3+ CCR3+1.4  ±  0.3 (20)2.0  ±  0.6 (14)2.1  ±  0.3 (20)
CD3+ CCR4+9.0  ±  1.1 (6)7.1  ±  0.6 (14)9.6  ±  2.7 (7)
CD3+ CCR5+7.9  ±  0.8 (20)9.9  ±  1.3 (14)13.1  ±  1.4** (20)
CD3+ CCR6+8.6  ±  1.3 (9)Not tested9.2  ±  0.7 (10)
CD3+ CXCR3+9.1  ±  1.1 (20)14.4  ±  1.9* (14)14.8  ±  1.5** (20)
CD3+ CXCR4+47.1  ±  8.1 (9)Not tested30.9  ±  5.3 (10)
  • PBMC from control healthy donors, relapsing–remitting (RR) MS, and progressive MS patients were separated and a three-step staining procedure, with mouse anti-chemokine receptor mAb followed by FITC-conjugated goat anti-mouse IgG and then PE-labeled anti-CD3 mAb, was performed as described in the text. Two-color flow cytometry was performed, and percentage of double-positive cells was analyzed and presented as mean ± SEM, with the number of patients in parentheses. ∗, P < 0.05 vs. controls; ∗∗, P < 0.005 vs. controls.